Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mannkind Corp. (MNKD)
NASDAQ:MNKD
Holding MNKD?
Track your performance easily
MNKD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.17 - $7.63
Previous Close$6.3
Volume7.22M
Average Volume (3M)2.51M
Market Cap
$1.74B
Enterprise Value$1.73B
Total Cash (Recent Filing)$251.59M
Total Debt (Recent Filing)$240.28M
Price to Earnings (P/E)89.6
Beta0.86
Next Earnings
Mar 04, 2025EPS Estimate
$0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding275,777,693
10 Day Avg. Volume2,911,970
30 Day Avg. Volume2,509,386
Standard Deviation0.18
R-Squared0.13
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-9.01
Price to Sales (P/S)6.50
Price to Cash Flow (P/CF)46.60
P/FCF Ratio54.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.64
Enterprise Value/Gross Profit12.67
Enterprise Value/Ebitda32.25
Forecast
1Y Price Target
$10.00Price Target Upside45.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
MannKind News
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe MNKD-101 program targets NTM lung disease and offers potential opportunities significantly larger than the current business.
Financial PerformanceTyvaso DPI royalties continue positive trajectory fueled by overall brand growth and strong uptake of the DPI formulation.
Product ApprovalsMNKD announced results from the Phase 3 INHALE-1 study which show strong potential for the approvability of Afrezza (inhaled insulin) in pediatrics.
Bears Say
Clinical DevelopmentSome lung toxicity was observed during the Phase 1 study of MNKD-201, with cough and FEV-1 drop noted, although these were transient and not dose-dependent.
Commercial RisksAfrezza makes up a small part of the valuation, and this is not expected to be needle-moving for the stock.
Financial NeedsRisks include clinical development challenges, commercial risks associated with royalties, and potential financial needs for raising capital.
---
Ownership Overview
3.02% Insiders
11.90% Mutual Funds
14.72% Other Institutional Investors
56.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $3.17 and its highest was $7.63 in the past 12 months.
What is Mannkind Corp.’s market cap?
Currently, no data Available
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Mar 04, 2025 which is in 73 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Nov 07, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.01.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is $0.03.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 275,777,680 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of $0.04 in its last earnings report, beating expectations of $0.03. Following the earnings report the stock price went down -0.677%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Among the largest hedge funds holding Mannkind Corp.’s share is Bruce & Co., Inc.. It holds Mannkind Corp.’s shares valued at 1M.
---
MannKind Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (45.99% Upside)
$10.00 (45.99% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 87%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 91.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.2%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.91%
Trailing 12-Months
Company Description
Mannkind Corp.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
---
MNKD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive overall sentiment with strong revenue growth and successful collaborations driving optimism. However, challenges like Afrezza headwinds and market difficulties in NTM lung disease were noted.Read More>---
MNKD Stock 12 Month Forecast
Average Price Target
$10.00
▲(45.99% Upside)
Technical Analysis
Best Analysts Covering MNKD
1 Year
1 Year Success Rate
4/8 ratings generated profit
1 Year Average Return
+35.58%
initiated a buy rating 6 months ago
Copying Brandon Folkes's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +35.58% per trade.
---